Medicilon(SH:688202) Xin Lang Zheng Quan·2025-12-03 06:12Group 1 - The core viewpoint of the news is that Medicy has experienced a significant stock price increase of 71.63% year-to-date, but has recently faced declines in the short term, with a drop of 9.16% over the last five trading days and 22.93% over the last 20 days [1] - As of December 3, Medicy's stock price is reported at 51.78 yuan per share, with a total market capitalization of 6.957 billion yuan [1] - The company has seen a net outflow of main funds amounting to 15.31 million yuan, with large orders showing a buy of 12.31 million yuan and a sell of 23.67 million yuan [1] Group 2 - Medicy's main business involves providing comprehensive new drug research and development services to pharmaceutical companies and other new drug research institutions, with revenue composition being 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research [1] - As of September 30, the number of shareholders for Medicy has increased by 27.83% to 16,500, while the average circulating shares per person have decreased by 21.96% to 8,149 shares [2] - For the period from January to September 2025, Medicy achieved an operating income of 843 million yuan, representing a year-on-year growth of 5.14%, while the net profit attributable to the parent company was -29.68 million yuan, showing a year-on-year increase of 76.93% [2] Group 3 - Since its A-share listing, Medicy has distributed a total of 158 million yuan in dividends, with cumulative distributions over the past three years amounting to 33.94 million yuan [3]